Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT03937830 2026-05-22

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

Phase 2 Active not recruiting

27 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT07391670 2026-05-15

IMFINZI-subQ

Phase 1 Recruiting

40 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

NCT03606967 2026-05-13

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Phase 2 Recruiting

70 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06058663 2026-05-13

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Phase 1 Recruiting

16 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT02453282 2026-05-12

MYSTIC

Phase 3 Active not recruiting

1,118 enrolled 40 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07081633 2026-05-12

TREMENDOUS-2

Phase 2 Active not recruiting

114 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03601455 2026-05-11

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Phase 2 Active not recruiting

13 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06921785 2026-05-11

ARTEMIDE-HCC01

Phase 3 Recruiting

1,220 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06564623 2026-05-08

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Phase 1 Recruiting

25 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

NCT05027425 2026-05-06

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Phase 2 Terminated

8 enrolled 9 charts

Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Hypertension, Portal

NCT07122089 2026-05-05

IOSPHERE

Phase 2 Recruiting

80 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03482102 2026-05-04

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

Phase 2 Active not recruiting

37 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT04585490 2026-05-04

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Phase 3 Recruiting

48 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07166406 2026-05-04

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Phase 3 Recruiting

226 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

Clinical Trials

Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

IMFINZI-subQ

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

MYSTIC

TREMENDOUS-2

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

ARTEMIDE-HCC01

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

IOSPHERE

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial